What should I know about proteinuria and nephrotic syndrome?
Incidence: In the pivotal Phase III trials, both the incidence and severity of proteinuria were increased in patients receiving Avastin. Across clinical studies, the incidence of grade 3–4 proteinuria (characterized as >3.5 g/24 hours) ranged up to 3.0% in Avastin-treated patients. Nephrotic syndrome was uncommon in clinical trials, occurring in 7 of 1459 (0.5%) patients.1 Monitoring: Patients should also be monitored for the development or worsening of proteinuria with serial urinalysis. Patients with 2+ or greater urine dipstick reading should undergo further assessment (eg, 24-hour urine collection).1 Management: In most clinical studies, Avastin was interrupted for ≥2 g of proteinuria/24 hours and resumed when proteinuria was <2 g/24 hours. Avastin should be discontinued in patients with nephrotic syndrome. Patients with moderate to severe proteinuria based on 24-hour collections should be monitored regularly until improvement and/or resolution is observed. The safety of continued
Related Questions
- Serum albumin levels are reduced in patients with nephrotic syndrome and gross proteinuria. Are serum Freelite levels also reduced in patients with proteinuria?
- Do glutathione-S-transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome?
- What should I know about proteinuria and nephrotic syndrome?
